Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061893 · ClinicalTrials.gov registry record · Phase 2
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
A Phase 2 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00061893 is a Phase 2 study that has completed, run by Children's Oncology Group. The registered enrollment target is 38 participants.
The verdict
NCT00061893, a Phase 2 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as vinblastine, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of Ewing's sarcoma by stopping blood flow to the tumor. Combining more than one chemotherapy drug with celecoxib may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining low-dose vinblastine and celecoxib with standard regimens of combination chemotherapy in treating patients who have newly-diagnosed metastatic Ewing's sarcoma family of tumors.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- DRUG ifosfamide
- DRUG doxorubicin hydrochloride
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2004-04 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061893
The ClinicalTrials.gov registry entry for NCT00061893 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00061893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00061893 about?
NCT00061893 is a clinical study titled "Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors". RATIONALE: Drugs used in chemotherapy, such as vinblastine, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of Ewing's sarcoma by stopping blood flow to the tumor. Combining more than one chemotherapy drug with celecoxib may kill mo...
What is the current status of trial NCT00061893?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2004-04. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00061893?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), ifosfamide (DRUG), doxorubicin hydrochloride (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00061893?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.